相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2021)
Comparing Propensity Score Methods Versus Traditional Regression Analysis for the Evaluation of Observational Data: A Case Study Evaluating the Treatment of Gram-Negative Bloodstream Infections
Joe Amoah et al.
CLINICAL INFECTIOUS DISEASES (2020)
Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae
Jesus Rodriguez-Bano et al.
CLINICAL MICROBIOLOGY REVIEWS (2018)
Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial
Pinyo Rattanaumpawan et al.
BMC INFECTIOUS DISEASES (2017)
Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study
Belen Gutierrez-Gutierrez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Effects of Group 1 versus Group 2 Carbapenems on the Susceptibility of Acinetobacter baumannii to Carbapenems: A Before and After Intervention Study of Carbapenem-Use Stewardship
Young Kyung Yoon et al.
PLOS ONE (2014)
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012
R. Phillip Dellinger et al.
CRITICAL CARE MEDICINE (2013)
Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review
Matthew E. Falagas et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2013)
Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology?
Dolores Sousa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Efficacy of Ertapenem for Treatment of Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
Vicki L. Collins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010
Chi-Chang Huang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence
David P. Nicolau et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis
Un-In Wu et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2012)
Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae
Nan-Yao Lee et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations
Olaf Burkhardt et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis
A. J. Brink et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Parenteral carbapenems
P. M. Shah
CLINICAL MICROBIOLOGY AND INFECTION (2008)
分享论文
